Development of tuberculosis in a patient treated with infliximab who had received prophylactic therapy with isoniazid.
Parra Ruiz
Jorge
J
Ortego Centeno
Norberto
N
Raya Alvarez
Enrique
E
D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D000995:Antitubercular Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D000069285:Infliximab; D007538:Isoniazid / Q000627:therapeutic use; D014397:Tuberculosis, Pulmonary / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000995:Antitubercular Agents; D000069285:Infliximab; D007538:Isoniazid